Építés alatt – nem éles oldal
Belépés
Csak meghívásosFázis nélkül

A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA.

A legfontosabb adatok

Ki végzi
Diakonhjemmet Hospital
Hol
Norvégia1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Csak meghívásos
Résztvevők
108 fő, tervezett
Kezdés
2024. júl. 29.
Várható befejezés
2027. dec. 1.
A vizsgálat típusa
Megfigyeléses, 4 csoport
A vizsgált kezelések
  • Methotrexate
  • Treatment as usual
A regiszteradat frissítve
2025. április 24.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults who took part in the MERINO trial of methotrexate for erosive hand osteoarthritis. It follows them for a longer time.

Életkor
18 Years and older
Nem
All
A betegség stádiuma
Hand osteoarthritis by ACR criteria, with pre-erosive or erosive changes on X-ray in at least 1 finger joint. Ultrasound must show inflammation in at least two finger joints. Finger pain must be 40-80 on a 0-100 scale, with hand symptoms on most days in the 6 weeks before.
Korábbi kezelés
People must have been in the MERINO trial. Paracetamol and/or NSAIDs did not relieve pain enough, could not be tolerated or could not be used. No steroid pills or muscle injections in the previous month. No joint injections or fluid draining in the hands in the 3 months before.
Biomarker vagy leletérték
Rheumatoid factor and anti-CCP antibodies must be negative.

A részvétel fő kizáró okai

  • Reasons methotrexate cannot be used, such as poor kidney or liver function, hepatitis B or C, lung fibrosis or low blood counts
  • Pregnancy, breastfeeding, planned pregnancy within 18 months, or no reliable birth control
  • Other inflammatory joint diseases such as rheumatoid arthritis, psoriatic arthritis or gout
  • Serious other illnesses, such as cancer, HIV, active tuberculosis or severe heart or lung disease
  • Other causes of hand symptoms, or hand surgery planned during the study

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization
  • Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound

Ki nem vehet részt

  • Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger
  • Oral or intra-muscular steroids in the previous month
  • Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
  • Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study
  • Disease-modifying osteoarthritis drugs (DMOADs) previous three months
  • Scheduled hand surgery during study participation
  • Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies
  • Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system
  • Contraindications to methotrexate:; Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2; Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis; Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia); Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections); Alcohol or other drug abuse in the last year; Intolerance to lactose
  • Analgesics or NSAIDs, unless stable dosage for ≥1 month
  • Planning to start other treatments for hand OA in the study participation period
  • Not able to adhere to the study visit schedule and protocol requirements

Egyéb feltételek

  • Eligible participants are those enrolled in the MERINO-trial (EudraCT number 2019-004641-33, Clincaltrials.gov number NCT04579848, REK ID 2020/187524, CTIS number 2023-510523-30-00)

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

In response to the high prevalence of synovitis in hand osteoarthritis (OA) and its association with pain, there\&amp;#39;s a compelling rationale for investigating the efficacy of MTX in managing inflammatory erosive hand OA. Recent guidelines highlight the need for large, well-designed trials to assess the effectiveness of MTX. A recent trial (METHODS study) showed promising pain reduction with MTX, but due to pandemic-related protocol changes, the duration of the study was limited to six months. The ongoing MERINO trial randomizes participants to MTX or placebo for one year. After completing the MERINO trial, several participants asked for MTX open label. In the subsequent MERINO:2 study, participants completing the trial will be invited to a structured follow-up after one year, including electronic questionnaires and hand radiographs, providing valuable long-term data on the effects of MTX in hand OA. Together, these trials aim to fill gaps in understanding the long-term impact of MTX in hand OA, particularly on structural progression.

A vizsgálat 4 csoportja

  • MTX -- MTX

    MERINO trial: randomized to methotrexate (MTX) MERINO:2 study: continues with MTX

    Kezelés: Methotrexate

  • MTX -- Treatment as usual

    MERINO trial: randomized to methotrexate (MTX) MERINO:2 study: continues without MTX

    Kezelés: Treatment as usual

  • Placebo -- MTX

    MERINO trial: randomized to placebo MERINO:2 study: continues with MTX

    Kezelés: Methotrexate

  • Placebo -- Treatment as usual

    MERINO trial: randomized to placebo MERINO:2 study: continues without MTX

    Kezelés: Treatment as usual

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Long-term Effects of Methotrexate in Adults With Erosive Hand Osteoarthritis: A 30-month Follow-up of Former MERINO Participants (MERINO:2).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. április 24.